Q32 Bio Inc (QTTB)

Over the past six months, Q32 Bio reported reduced GAAP net loss due to decreased research and development expenses following a corporate restructuring. The company completed enrollment in Part B of its Phase 2a clinical trial for bempikibart in alopecia areata, with topline results expected in the first half of 2026. Q32 Bio sold its complement inhibitor ADX-097 to Akebia Therapeutics, leading to a surge in QTTB stock. Analyst ratings are mixed, with Oppenheimer maintaining an "Outperform" rating. There were insider trading activities and board changes. The share price increased by 30.28% from February 4, 2025, to February 3, 2026.

As a clinical-stage biotechnology company, Q32 Bio, Inc. does not currently have commercialized products or services generating revenue, therefore, there is no discernible demand seasonality for its products or services at this stage.

Q32 Bio, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases. Their lead product candidate, Bempikibart, is being evaluated in Phase 2 clinical trials for alopecia areata. The company restructured in February 2025 to prioritize bempikibart development and sold the ADX-097 project.

Q32 Bio, Inc. is headquartered in Waltham, Massachusetts, United States. Its primary operations are focused on research and development, with clinical trials for bempikibart ongoing.

Q32 Bio's brand reputation is shaped by its clinical development progress and strategic corporate decisions. The company's focus is on transforming the lives of patients with alopecia areata and other autoimmune and inflammatory diseases. Corporate restructuring and focus on bempikibart, the sale of ADX-097, clinical trial progress, analyst sentiment, and insider stock sales have all affected its reputation. Overall, Q32 Bio's reputation is that of a clinical-stage biotech making strategic moves to advance its lead candidate, with financial analysts holding mixed but generally cautious views.

Q32 Bio, Inc. has a significant institutional ownership presence, with 69 institutional owners and shareholders holding a total of 8,547,165 shares as of recent filings. Major institutional owners include Orbimed Advisors Llc, Atlas Venture Life Science Advisors, LLC, Carlyle Group Inc., Acorn Capital Advisors, Llc, Vanguard Group Inc, Arch Venture Corp, Monaco Asset Management SAM, Pfizer Inc, Sanofi, and VTSMX - Vanguard Total Stock Market Index Fund Investor Shares.